Literature DB >> 32953208

Drug-eluting balloon treatment in femoropopliteal in-stent restenosis of different lengths.

Berkan Özpak1, Mustafa Çağdaş Çayır2.   

Abstract

BACKGROUND: In this study, we present one-year results of drugeluting balloon treatment of femoropopliteal in-stent restenosis.
METHODS: A total of 62 patients (48 males, 14 females; mean age 64.2±9.1 years; range, 54 to 81 years) who underwent drugeluting balloon stenting for femoropopliteal in-stent restenosis between August 2013 and October 2017 were included in the study. The patients were classified into three groups based on the narrowing length of stenosis in the stents. Group/Class 1 (n=17): narrowing <1/2 of the stent length; Group/Class 2 (n=22): narrowing >1/2 of the stent length, not totally occluded; and Group/Class 3 (n=23): totally occluded. In-stent restenosis was treated with drug-eluting balloon treatment.
RESULTS: There was a significant difference among all classes in terms of in-stent restenosis. The length of stenosis was a predictor for in-stent restenosis. The mean stent length was 107.7±24.6 mm in Group 1, 164.6±17.9 mm in Group 2, and 180±19.3 mm in Group 3. For non-occluded in-stent restenosis, restenosis rate at one year after balloon angioplasty was 47.1% in Group 1, 86.4% in Group 2, and 95.7% in Group 3. Femoropopliteal bypass was performed in five patients in whom treatment failed. None of the patients required amputation.
CONCLUSION: The length of in-stent restenosis in the femoropopliteal arterial stents is an important predictor for recurrent stenosis, when re-flow is achieved with drug-eluting balloons.
Copyright © 2020, Turkish Society of Cardiovascular Surgery.

Entities:  

Keywords:  Drug eluting balloon; in-stent restenosis; peripheral arterial disease

Year:  2020        PMID: 32953208      PMCID: PMC7493602          DOI: 10.5606/tgkdc.dergisi.2020.18980

Source DB:  PubMed          Journal:  Turk Gogus Kalp Damar Cerrahisi Derg        ISSN: 1301-5680            Impact factor:   0.332


  16 in total

1.  Treatment of complex arteriosclerotic lesions with nitinol stents in the superficial femoral and popliteal arteries: a midterm follow-up.

Authors:  Herbert F Lugmayr; Hermann Holzer; Manfred Kastner; Harald Riedelsberger; Alexandra Auterith
Journal:  Radiology       Date:  2002-01       Impact factor: 11.105

2.  Patterns and mechanisms of in-stent restenosis. A serial intravascular ultrasound study.

Authors:  R Hoffmann; G S Mintz; G R Dussaillant; J J Popma; A D Pichard; L F Satler; K M Kent; J Griffin; M B Leon
Journal:  Circulation       Date:  1996-09-15       Impact factor: 29.690

3.  Drug-eluting balloons for the treatment of the superficial femoral artery in-stent restenosis: 2-year follow-up.

Authors:  Vittorio Virga; Eugenio Stabile; Giancarlo Biamino; Luigi Salemme; Angelo Cioppa; Giuseppe Giugliano; Tullio Tesorio; Linda Cota; Grigore Popusoi; Armando Pucciarelli; Giovanni Esposito; Bruno Trimarco; Paolo Rubino
Journal:  JACC Cardiovasc Interv       Date:  2014-03-14       Impact factor: 11.195

4.  Paclitaxel-eluting balloon vs. standard angioplasty to reduce recurrent restenosis in diabetic patients with in-stent restenosis of the superficial femoral and proximal popliteal arteries: the DEBATE-ISR study.

Authors:  Francesco Liistro; Paolo Angioli; Italo Porto; Lucia Ricci; Kenneth Ducci; Simone Grotti; Giovanni Falsini; Giorgio Ventoruzzo; Filippo Turini; Guido Bellandi; Leonardo Bolognese
Journal:  J Endovasc Ther       Date:  2014-02       Impact factor: 3.487

Review 5.  An overview of optimal endovascular strategy in treating the femoropopliteal artery: mechanical, biological, and procedural factors.

Authors:  Nicolas W Shammas
Journal:  Int J Angiol       Date:  2013-03

6.  Stenting of femoropopliteal lesions using interwoven nitinol stents.

Authors:  Alexander A Brescia; Brian M Wickers; Juan Carlos Correa; Mathew R Smeds; Donald L Jacobs
Journal:  J Vasc Surg       Date:  2015-03-07       Impact factor: 4.268

7.  Classification and clinical impact of restenosis after femoropopliteal stenting.

Authors:  Atsushi Tosaka; Yoshimitsu Soga; Osamu Iida; Takayuki Ishihara; Keisuke Hirano; Kenji Suzuki; Hiroyoshi Yokoi; Shinsuke Nanto; Masakiyo Nobuyoshi
Journal:  J Am Coll Cardiol       Date:  2012-01-03       Impact factor: 24.094

8.  Sirolimus-eluting versus bare nitinol stent for obstructive superficial femoral artery disease: the SIROCCO II trial.

Authors:  Stephan H Duda; Marc Bosiers; Johannes Lammer; Dierk Scheinert; Thomas Zeller; Alexander Tielbeek; John Anderson; Benjamin Wiesinger; Gunnar Tepe; Alexandra Lansky; Catharina Mudde; Hans Tielemans; Jean P Bérégi
Journal:  J Vasc Interv Radiol       Date:  2005-03       Impact factor: 3.464

9.  Primary patency of femoropopliteal arteries treated with nitinol versus stainless steel self-expanding stents: propensity score-adjusted analysis.

Authors:  Schila Sabeti; Martin Schillinger; Jasmin Amighi; Camillo Sherif; Wolfgang Mlekusch; Ramazanali Ahmadi; Erich Minar
Journal:  Radiology       Date:  2004-08       Impact factor: 11.105

10.  Drug-Coated Balloon Versus Standard Balloon for Superficial Femoral Artery In-Stent Restenosis: The Randomized Femoral Artery In-Stent Restenosis (FAIR) Trial.

Authors:  Hans Krankenberg; Thilo Tübler; Maja Ingwersen; Michael Schlüter; Dierk Scheinert; Erwin Blessing; Sebastian Sixt; Arne Kieback; Ulrich Beschorner; Thomas Zeller
Journal:  Circulation       Date:  2015-10-07       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.